P540: The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus surveyECCO’23 CopenhagenYear: 2023
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1)*;Kyriacou, M.(2);Moran, G.(3);
(1)Nottingham University Hospitals NHS Trust, Inflammatory Bowel Disease, Nottingham, United Kingdom;(2)Nottingham University Hospitals NHS Trust, Gastroenterology- Surgery Division, Nottingham, United Kingdom;(3)Nottingham NIHR Biomedical Research Centre, Translational Medical Sciences- School of Medicine- The University of Nottingham, Nottingham, United Kingdom;
P541: Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.ECCO’23 CopenhagenYear: 2023
Authors: Guerra Marina, I.(1)*;Barros, F.(2);Mesonero, F.(3);de Francisco, R.(4);Cañete, F.(5,6);Benítez, J.M.(7);Sicilia, B.(8);Martín Arranz, M.D.(9);de Castro, L.(10);Carbajo, A.Y.(11);Gutiérrez, A.(6,12);Calvo, M.(13);Casanova, M.J.(6,14);González-Muñoza, C.(15);Miguel, M.(16);Alfambra, E.(6,17);Rivero, M.(18);Lucendo, A.J.(6,19);Tardillo, C.A.(20);Almela, P.(21);Bujanda, L.(6,22);Van Domselaar, M.(23);Ramos, L.(24);Fernández Sánchez, M.(25);Hinojosa, E.(26);Verdejo, C.(27);Gimenez, A.(28);Piqueras, M.(29);Rodríguez-Lago, I.(30);Manceñido, N.(31);Pérez Calle, J.L.(32);Moreno, M.D.P.(33);Delgado, P.G.(34);Antolín, B.(35);Ramírez de la Piscina, P.(36);Bermejo, F.(37);Carracedo, Á.(38);Domènech, E.(5,6);Gisbert, J.P.(6,14);
(1)Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain;(2)Fundación Pública Galega de Medicina Xenómica. Sergas., Unidad de Medicina Molecular, Santiago de Compostela, Spain;(3)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(4)Hospital Universitario Central de Asturias- Instituto de Investigación Sanitaria del Principado de Asturias ISPA-, Gastroenterology, Oviedo, Spain;(5)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(6)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Spain, Spain;(7)Hospital Universitario Reina Sofía e Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Gastroenterology, Córdoba, Spain;(8)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(9)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(10)Hospital Alvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo- Instituto de Investigación Biomédica Galicia Sur, Gastroenterology, Vigo, Spain;(11)Hospital Universitario Rio Hortega, Gastroenterology, Valladolid, Spain;(12)Hospital General Universitario Dr Balmis de Alicante. ISABIAL., Gastroenterology, Alicante, Spain;(13)Hospital Universitario Puerta de Hierro-Majadahonda, Gastroenterology, Madrid, Spain;(14)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- UAM, Gastroenterology, Madrid, Spain;(15)Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(16)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(17)Hospital Clínico Universitario “Lozano Blesa” e Instituto de Investigación Sanitaria de Aragón IIS Aragón, Hospital Clínico Universitario “Lozano Blesa” e Instituto de Investigación Sanitaria de Aragón IIS Aragón, Zaragoza, Spain;(18)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology, Santander, Spain;(19)Hospital General de Tomelloso, Gastroenterology, Ciudad Real, Spain;(20)Hospital Universitario Nuestra Señora Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(21)Hospital General Universitari de Castelló, Gastroenterology, Castelló, Spain;(22)Hospital Donostia/Instituto Biodonostia- Universidad del País Vasco UPV/EHU, Gastroenterology, Donostia/San Sebastián, Spain;(23)Hospital Universitario de Torrejón y Universidad Francisco de Vitoria, Gastroenterology, Madrid, Spain;(24)Hospital Universitario de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain;(25)Hospital General Universitario de Elche, Gastroenterology, Alicante, Spain;(26)Hospital de Manises, Gastroenterology, Valencia, Spain;(27)Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain;(28)Hospital Sant Joan de Déu-Althaia, Gastroenterology, Manresa, Spain;(29)Consorci Sanitari Terrasa, Gastroenterology, Terrasa, Spain;(30)Hospital de Galdakao, Gastroenterology, Galdakao, Spain;(31)Hospital Universitario Infanta Sofía, Gastroenterology, San Sebastián de los Reyes- Madrid, Spain;(32)Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain;(33)Hospital General La Mancha Centro, Gastroenterology, Alcázar de San Juan- Ciudad Real, Spain;(34)Hospital General de Granollers, Gastroenterology, Granollers, Spain;(35)Hospital Clínico Universitario de Valladolid, Gastroenterology, Valladolid, Spain;(36)Hospital Universitario de Áraba, Gastroenterology, Áraba, Spain;(37)Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain;(38)Fundación Pública Galega de Medicina Xenómica. Sergas, Unidad de Medicina Molecular, Santiago de Compostela, Spain;On behalf of the ENEIDA project of GETECCU.
P542: Short term efficacy, safety and thromboembolic risk of tofacitinib in moderate to severe Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Cingolani, L.(1);Barberio, B.(1)*;Zelante, A.(2);Ribaldone, D.(3);Testa, G.(3);Bertani, L.(4);Buda, A.(5);Zingone, F.(1);Savarino, E.V.(1);
(1)Padua University Hospital, Surgery- Oncology and Gastroenterology, Padua, Italy;(2)Rovigo "Santa Maria della Misericordia" Hospital, Gastroenterology Unit, Rovigo, Italy;(3)University Hospital “Città della salute e della scienza”, Gastroenterology Unit, Turin, Italy;(4)Ospedale Policlinico San Martino, Gastroenterology Unit, Genoa, Italy;(5)Santa Maria del Prato Hospital, Gastroenterology Unit, Feltre, Italy;
P543: Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice – Results of a nationwide, prospective, multicenter study in Germany (MUCUS)ECCO’23 CopenhagenYear: 2023
Authors: BaumgartMD PhD MBA, D.C.(1)*;Stallmach, A.(2);Schubert, A.(3);Howaldt, S.(4);von Arnim, U.(5);Ochsenkühn, T.(6);Stein, J.(7);Lügering, A.(8);Schmidt, D.(9);Schulz, M.(10);Fischer, A.(10);
(1)Charité - Universitätsmedizin Berlin, Medizinische Klinik m.S. Hepatologie und Gastreonterologie, Berlin, Germany;(2)Universitätsklinikum Jena, Klinik für Innere Medizin IV Gastroenterologie- Hepatologie- Infektiologie- Interdisziplinäre Endoskopie, Jena, Germany;(3)Gastroenterologie am Bayerischen Platz, Gastroenterologie, Berlin, Germany;(4)Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen, Immunologie, Hamburg, Germany;(5)Universitätsklinikum Magdeburg, Universitätsklinik für Gastroenterologie- Hepatologie und Infektiologie, Magdeburg, Germany;(6)Isarklinikum, Klinik für Gastroenterologie- Hepatologie und Gastroenterologische Onkologie, München, Germany;(7)DGD Kliniken Frankfurt Sachsenhausen, Abteilung Gastroenterologie/Ernährungsmedizin, Frankfurt am Main, Germany;(8)MVZ Portal 10, Zentrum für Leber-- Magen- und Darmerkrankungen, Münster, Germany;(9)Charité - Universitätsmedizin Berlin, Medizinsiche Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Germany;(10)Charité - Universitätsmedizin Berlin, Medizinische Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Germany;
P544: Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patientsECCO’23 CopenhagenYear: 2023
Authors: Jessen, B.(1);Tóth, M.(1)*;Freise, I.(1);Staudacher, J.(1);Haag, L.M.(1);Kredel, L.(1);Schumann, M.(1);Weidinger, C.(1);Sonnenberg, E.(1);Siegmund, B.(1);
(1)Charité Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie- Infektiologie und Rheumatologie, Berlin, Germany;
P545: Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseasesECCO’23 CopenhagenYear: 2023
Authors: Pueschel, L.(1);Kockelmann, F.(2);Kueck, M.(3);Tegtbur, U.(3);Seidler, U.(1);Lenzen, H.(1);Attaran-Bandarabadi, M.(4);Bachmann, O.(5);Wedemeyer, H.(1);Wiestler, M.(1)*;
(1)Hannover Medical School, Gastroenterology- Hepatology and Endocrinology, Hannover, Germany;(2)Klinikum Dortmund, Surgical Department, Dortmund, Germany;(3)Hannover Medical School, Institute of Sports Medicine, Hannover, Germany;(4)General Practice, Internal Medicine, Ronnenberg, Germany;(5)Siloah St. Trudpert Klinikum, Internal Medicine, Pforzheim, Germany;
P546: Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparisonECCO’23 CopenhagenYear: 2023
Authors: Reinisch, W.(1)*;Panaccione, R.(2);Duijvestein, M.(3);Ceballos Santos, D.(4);Melmed, G.Y.(5);Xuan, S.(6);Wegrzyn, L.(6);Levy, G.(6);Ilo, D.(6);Sanchez Gonzalez, Y.(6);
(1)Medical University of Vienna, Department of Internal Medicine III, Wien, Austria;(2)University of Calgary, Department of Medicine- Division of Gastroenterology and Hepatology, Calgary, Canada;(3)Radboud University Medical Center, Department of Gastroenterology, Nijmegen, Netherlands Antilles;(4)Hospital Universitario Doctor Negrin, Department of Gastroenterology, Las Palmas, Spain;(5)Cedars-Sinai Medical Center, n/a, Los Angeles, United States;(6)AbbVie Inc., n/a, Chicago, United States;
P547: Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Barnes, E.(1)*;Zhang, X.(2);Long, M.(3);Herfarth, H.(1);Kappelman, M.(4);
(1)University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(2)University of North Carolina School of Medicine, Center for Gastrointestinal Biology and Disease, Chapel Hill, United States;(3)University of North Carolina at Chapel Hill, Division of Gastroenterology & Hepatology, Chapel Hill, United States;(4)University of North Carolina at Chapel Hill, Division of Pediatric Gastroenterology, Chapel Hill, United States;
P548: Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab StudiesECCO’23 CopenhagenYear: 2023
Authors: Atreya, R.(1)*;Irving, P.(2);Fujiya, M.(3);Colombel, J.F.(4);Danese, S.(5);Peyrin-Biroulet, L.(6);Bessissow, T.(7);Panaccione, R.(8);D'Haens, G.(9);van Haaren, S.(10);Neimark, E.(11);Zambrano, J.(12);Zhang, Y.(13);Kligys, K.(10);Ferrante, M.(14);
(1)Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine, Erlangen, Germany;(2)St Thomas' Hospital, IBD Centre- Department of Gastroenterology, London, United Kingdom;(3)Asahikawa Medical University, 3Department of Medicine- Division of Metabolism and Biosystemic Science- Gastroenterology and Hematology/Oncology, Asahikawa, Japan;(4)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York City, United States;(5)Humanitas Clinical and Research Center – IRCCS, IBD Center- Department of Gastroenterology, Rozzano, Italy;(6)University Hospital of Nancy-Brabois, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(7)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(8)University of Calgary Cumming School of Medicine, Inflammatory Bowel Disease Unit, Calgary, Canada;(9)Amsterdam University Medical Centers- Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands;(10)AbbVie, Global Medical Affairs, North Chicago, United States;(11)AbbVie, Clinical Development, North Chicago, United States;(12)AbbVie, US Medical Affairs, North Chicago, United States;(13)AbbVie, Statistics, North Chicago, United States;(14)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P549: One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United StatesECCO’23 CopenhagenYear: 2023
Authors: Dalal, R.(1)*;Sharma, P.(2);Bains, K.(3);Pruce, J.(1);Allegretti, J.(1);
(1)Brigham and Women's Hospital- Harvard Medical School, Gastroenterology- Hepatology and Endoscopy, Boston, United States;(2)Pfizer, Gastroenterology, New York, United States;(3)Brigham and Women's Hospital, Nutrition, Boston, United States;
P550: Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 yearsECCO’23 CopenhagenYear: 2023
Authors: Taxonera, C.(1)*;Ha, C.(2);del Pilar Fortes, M.(3);Gardiner, S.(3);Mundayat, R.(3);Ghosh, S.(4);Connor, S.J.(5);
(1)Inflammatory Bowel Disease- Unit Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos, Madrid, Spain;(2)-, Division of Gastroenterology and Hepatology- Mayo Clinic, Scottsdale- Arizona, United States;(3)-, Pfizer Inc, New York- NY, United States;(4)APC Microbiome Ireland, College of Medicine and Health- University College Cork, Cork, Ireland;(5)-, Liverpool Hospital- University of New South Wales- Ingham Institute of Applied Medical Research, Sydney, Australia;
P551: Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn's disease: application and prospective validation.ECCO’23 CopenhagenYear: 2023
Authors: Macedo Silva, V.(1)*;Ferreira, A.I.(1);Lima Capela, T.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Boal Carvalho, P.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
(1)Hospital da Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal;
P552: Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Cohen, Y.(1);Fischman, M.(1);Waterman, M.(2);Dolnikov, K.(3);Azzam, Z.S.(3);Ghersin, I.(2)*;
(1)Faculty of Medicine- Hebrew University of Jerusalem, Department of Military Medicine, Jerusalem, Israel;(2)Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel;(3)Rambam Health Care Campus, Department of Internal Medicine "B", Haifa, Israel;
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indicationsECCO’23 CopenhagenYear: 2023
Authors: Ghosh, S.(1)*;Long, M.(2);Ott, E.(3);Gasink, C.(3);Baker, T.(4);Godwin, B.(3);Miao, Y.(4);Loftus, E.(5);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(3)Janssen, Scientific Affairs, Horsham, United States;(4)Janssen, Research & Development, Spring House, United States;(5)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;
